Evaluation of the effect of betapropiolactone/ultraviolet irradiation (BPL/UV) treatment of source plasma on hepatitis transmission by factor IX complex in chimpanzees

Thromb Haemost. 1980 Dec 19;44(3):138-42.

Abstract

To evaluate the safety of a beta-Propiolactone/Ultraviolet (BPL/UV), irradiated Factor IX complex preparation we inoculated 8 chimpanzees with 25 units Factor IX/Kilo from a pool of 5 production lots which had been treated in this manner. These lots were derived from approximately 1,000 donors. Animals were followed with weekly tests for hepatitis B serologic markers and transaminases, and biweekly liver biopsies, for 6 months. No evidence of transmission of hepatitis B, or non-A, non-B viruses was observed. To further evaluate the BPL/UV procedure a plasma pool was intentionally contaminated with hepatitis B virus and one half of the pool treated with BPL/UV. Factor IX complex was isolated from the treated and untreated pools and each was inoculated into 4 chimpanzees. The Factor IX derived from untreated plasma infected all four animals with an average incubation period of 10.5 weeks, whereas that prepared from PBL/UV treated plasma infected only one of four animals with an incubation period of 21 weeks. These results were interpreted as suggesting that BPL/UV can inactivate approximately 99.9% of hepatitis B virus infectivity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antiviral Agents
  • Factor IX / adverse effects*
  • Female
  • Follow-Up Studies
  • Hepatitis B / microbiology
  • Hepatitis B / prevention & control
  • Hepatitis B / transmission*
  • Hepatitis B virus / pathogenicity*
  • Lactones / therapeutic use*
  • Male
  • Pan troglodytes
  • Propiolactone / therapeutic use*
  • Sterilization
  • Ultraviolet Therapy*

Substances

  • Antiviral Agents
  • Lactones
  • Propiolactone
  • Factor IX